PMC:7279430 / 42187-42448
Annnotations
LitCovid-PD-FMA-UBERON
{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T132","span":{"begin":237,"end":242},"obj":"Body_part"}],"attributes":[{"id":"A132","pred":"fma_id","subj":"T132","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Matricaria recutita L. α-bisabolol oxide A (13.4–55.9%), α-bisabolol oxide B (8.4–25.1%), bisabolone oxide A (2.9−11.4%), cis−bicycloether (= (Z)−spiroether) (3.6–17.7%), and (E)-β-farnesene (1.9–10.4%) i Plaque reduction assay (RC-37 cells), HSV-2 1.5 [57]"}
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"2282","span":{"begin":0,"end":21},"obj":"Species"},{"id":"2283","span":{"begin":245,"end":250},"obj":"Species"}],"attributes":[{"id":"A2282","pred":"tao:has_database_id","subj":"2282","obj":"Tax:127986"},{"id":"A2283","pred":"tao:has_database_id","subj":"2283","obj":"Tax:10310"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Matricaria recutita L. α-bisabolol oxide A (13.4–55.9%), α-bisabolol oxide B (8.4–25.1%), bisabolone oxide A (2.9−11.4%), cis−bicycloether (= (Z)−spiroether) (3.6–17.7%), and (E)-β-farnesene (1.9–10.4%) i Plaque reduction assay (RC-37 cells), HSV-2 1.5 [57]"}
LitCovid-PD-CLO
{"project":"LitCovid-PD-CLO","denotations":[{"id":"T449","span":{"begin":42,"end":43},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T450","span":{"begin":76,"end":77},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T451","span":{"begin":108,"end":109},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T452","span":{"begin":237,"end":242},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"Matricaria recutita L. α-bisabolol oxide A (13.4–55.9%), α-bisabolol oxide B (8.4–25.1%), bisabolone oxide A (2.9−11.4%), cis−bicycloether (= (Z)−spiroether) (3.6–17.7%), and (E)-β-farnesene (1.9–10.4%) i Plaque reduction assay (RC-37 cells), HSV-2 1.5 [57]"}
LitCovid-PD-CHEBI
{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T764","span":{"begin":26,"end":35},"obj":"Chemical"},{"id":"T765","span":{"begin":36,"end":41},"obj":"Chemical"},{"id":"T767","span":{"begin":60,"end":69},"obj":"Chemical"},{"id":"T768","span":{"begin":70,"end":75},"obj":"Chemical"},{"id":"T770","span":{"begin":102,"end":107},"obj":"Chemical"},{"id":"T772","span":{"begin":182,"end":191},"obj":"Chemical"}],"attributes":[{"id":"A764","pred":"chebi_id","subj":"T764","obj":"http://purl.obolibrary.org/obo/CHEBI_125"},{"id":"A765","pred":"chebi_id","subj":"T765","obj":"http://purl.obolibrary.org/obo/CHEBI_25741"},{"id":"A766","pred":"chebi_id","subj":"T765","obj":"http://purl.obolibrary.org/obo/CHEBI_29356"},{"id":"A767","pred":"chebi_id","subj":"T767","obj":"http://purl.obolibrary.org/obo/CHEBI_125"},{"id":"A768","pred":"chebi_id","subj":"T768","obj":"http://purl.obolibrary.org/obo/CHEBI_25741"},{"id":"A769","pred":"chebi_id","subj":"T768","obj":"http://purl.obolibrary.org/obo/CHEBI_29356"},{"id":"A770","pred":"chebi_id","subj":"T770","obj":"http://purl.obolibrary.org/obo/CHEBI_25741"},{"id":"A771","pred":"chebi_id","subj":"T770","obj":"http://purl.obolibrary.org/obo/CHEBI_29356"},{"id":"A772","pred":"chebi_id","subj":"T772","obj":"http://purl.obolibrary.org/obo/CHEBI_39237"}],"text":"Matricaria recutita L. α-bisabolol oxide A (13.4–55.9%), α-bisabolol oxide B (8.4–25.1%), bisabolone oxide A (2.9−11.4%), cis−bicycloether (= (Z)−spiroether) (3.6–17.7%), and (E)-β-farnesene (1.9–10.4%) i Plaque reduction assay (RC-37 cells), HSV-2 1.5 [57]"}
LitCovid-sentences
{"project":"LitCovid-sentences","denotations":[{"id":"T344","span":{"begin":0,"end":261},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Matricaria recutita L. α-bisabolol oxide A (13.4–55.9%), α-bisabolol oxide B (8.4–25.1%), bisabolone oxide A (2.9−11.4%), cis−bicycloether (= (Z)−spiroether) (3.6–17.7%), and (E)-β-farnesene (1.9–10.4%) i Plaque reduction assay (RC-37 cells), HSV-2 1.5 [57]"}